30 Must-See Tweets from AAO 2017

November 21, 2017

It was a privilege to deliver

It was a privilege to deliver #AAO2017 Extended Dosing of #Anti-VEGF Agents in #RetinalDiseases Course: An Evidence Based Approach w/ Lloyd Clark, Rahul Khurana & John Payne. Using data to drive optimal outcomes. @OphthTimes#ModernRetinapic.twitter.com/JcsAWeslIP

- Charles Wykoff MD (@TXRetinaSurgeon) November 13, 2017
 

More from @TXRetinaSurgeon (part 2) @aao_ophth#AAO2017#ModernRetinapic.twitter.com/qkib8yfKen

- Ophthalmology Times (@OphthTimes) November 12, 2017
 

Hear what @TXRetinaSurgeon had to say about day two of #Retina subspecialty day at #AAO2017#ModernRetina (part 1) pic.twitter.com/n4B5TofAEZ

- Ophthalmology Times (@OphthTimes) November 12, 2017
 

Dr. Spaide on day one of #Retina subspecialty day #AAO2017#ModernRetinapic.twitter.com/Gr8tcyxdSM

- Ophthalmology Times (@OphthTimes) November 12, 2017
 

#DRCR Protocol U: Significant anatomic benefit with combination steroid & anti-VEGF dosing for recalcitrant #DME. No benefit of combination dosing seen on change in mean BCVA compared to anti-VEGF monotherapy. #AAO2017@OphthTimes#ModernRetinapic.twitter.com/F3vjYiExEz

- Charles Wykoff MD (@TXRetinaSurgeon) November 11, 2017
 

Dr. Emmett Cunningham reporting on mosquito-borne uveitis showing rates are growing; ZIka "followed the trade winds" to get to the US #AAO2017@aao_ophth#ModernRetina

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Dr. James Philip Dunn, Jr.: Primary vitreoretinal lymphoma is "the only one" that needs biopsy in uveitis. @aao_ophth#AAO2017#ModernRetina

- Michelle Dalton (@MDaltonELS) November 11, 2017
 

Phase 2 Protocol U found that ranibizumab monotherapy and combination with dexamethasone in center-involved DME had similar vision outcomes at 24 wks. Anatomic outcome was better with combination therapy. -- Judy Kim, MD #ModernRetina#AAO2017

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Greater drying effect for the combination dexamethasone/ranibizumab group compared to ranibizumab alone, but for nearly all macular diseases the change in macular thickness shows poor correlation to change in visual acuity. -- Rick Spaide, MD #ModernRetina#AAO2017

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Protocol U results! Adding dexamethasone does not improve visual acuity as compared to ranibizumab alone in eyes with persistent diabetic macular edema -- Rick Spaide, MD #ModernRetina#AAO2017@aao_ophth

- Ophthalmology Times (@OphthTimes) November 11, 2017

Next


 

OCT angiography may help detect non-exudative CNV that can be followed for growth and flow prior to exudation seen on OCT. -- Judy Kim, MD #AAO2017#ModernRetina@aao_ophth

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Enjoyed speaking with @TXRetinaSurgeon yesterday about #Retina subspecialty day @aao_ophth#AAO2017#ModernRetinapic.twitter.com/hAGFsLxr4N

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Dr. Srinivas R. Sadda: New term for atrophy--Complete RPE and outer retinal atrophy (complete (c)RORA); GA is a subset of cRORA that excludes the region of presumptive CNV. @aao_ophth#AAO2017#ModernRetina

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

Inhibition of complement cascade with APL-2 targeting of C3 shows positive efficacy results in phase 2 #FILLY trial. Dose dependent slowing of #GA lesion growth = bringing new hope to patients with #AMD. Forward Together! #AAO2017@OphthTimes#ModernRetinapic.twitter.com/wPTJZQvEVk

- Charles Wykoff MD (@TXRetinaSurgeon) November 11, 2017
 

Watch part 1 of our Facebook live from last night at #AAO2017 with our #ModernRetina members @drrishisingh@TXRetinaSurgeon & Dr's Brown & Spaide!

Watch it here: https://t.co/lGqxn5rIol

- Ophthalmology Times (@OphthTimes) November 11, 2017
 

HAWK and HARRIER trial of brolucizumab vs aflibercept for wet AMD found visual and anatomic benefit of brolucizumab. -- Judy Kim, MD #ModernRetina#AAO2017

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

"So far we have had a smorgasbord of Retina by great speakers. The day is going to finish with a lineup of wonderful late breakers." -- Rick Spaide, MD #ModernRetina#AAO2017

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

Enjoyed speaking with @drrishisingh today at #AAO2017#ModernRetinapic.twitter.com/ydW4He5mHR

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

Caroline Baumal MD makes strong case incorporating OCT-Angiography into #Retina clinical practice at #AAO2017 while Karl Csaky MD makes strong counter argument - software has a long way to go before seamless integration. @OphthTimes#ModernRetinapic.twitter.com/YxAMbBGL3H

- Charles Wykoff MD (@TXRetinaSurgeon) November 10, 2017
 

Rick Ferris MD Delivers excellent Charles Schepens lecture on Clinical Trials Past, Present & Future #AAO2017. Thank you for your contributions to #Retina – your hand has guided our field for decades & we are better for it. @OphthTimes#ModernRetina@RetinaSpecialstpic.twitter.com/Sf5fORQJke

- Charles Wykoff MD (@TXRetinaSurgeon) November 10, 2017

Previous

Next


 

Privilege joining outstanding #Retina colleagues during inaugural Research Scholar Honoree Program recognizing excellent resident and retina fellow research. The Future is Bright! Rick Spaide MD delivers keynote. #AAO2017@OphthTimes#ModernRetina@RetinaSpecialstpic.twitter.com/ZUMmY3wUCc

- Charles Wykoff MD (@TXRetinaSurgeon) November 10, 2017
 

New approaches to #DME treatment are expanding management options. #AAO2017@OphthTimes#ModernRetinahttps://t.co/2NTOEq2plx

- Charles Wykoff MD (@TXRetinaSurgeon) November 10, 2017
 

#ModernRetina#AAO2017 ... Size does matter! https://t.co/IV4cCfeng9

- Michelle Dalton (@MDaltonELS) November 10, 2017
 

Third talk demonstrating ILM flaps! HOT topic trending at the surgical retina section. -- Dave Brown, MD, commenting #ModernRetina#AAO2017pic.twitter.com/myPgVbaZ0K

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

Evaluation of IRIS registry data of 27,489 eyes that underwent RD repair found reattachment success rate at year 1 was 87.9% -- Judy Kim, MD, commenting on Retina SubSpecialty Day #ModernRetina#AAO2017

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

Dr. Steve Charles, the "master of disaster," demonstrating retinectomy techniques -- Dave Brown, MD #ModernRetina#AAO2017pic.twitter.com/CdHtzMlXHR

- Ophthalmology Times (@OphthTimes) November 10, 2017
 

Heard at Retina Scholar Program: surgeons who reapply PI after lid speculum have sevenfold reduction in rates of endophthalmitis compared to those who don't reapply or who reapply before lid speculum #ModernRetina#AAO2017

- Michelle Dalton (@MDaltonELS) November 9, 2017
 

Heard during the Research Scholar Program: Dendritic cells may have protective effect in type 2 LCA #ModernRetina#AAO2017

- Michelle Dalton (@MDaltonELS) November 9, 2017
 

Meet our 2017 #AAO street team members:https://t.co/iaWkOWADVz#ModernRetina#AAO2017pic.twitter.com/F7BHhwAttl

- Ophthalmology Times (@OphthTimes) November 9, 2017
 

Follow our #AAO2017 coverage from our #ModernRetina street team https://t.co/9gb35TR9F7pic.twitter.com/cLeXDlRhyd

- Ophthalmology Times (@OphthTimes) November 6, 2017

Previous